Raffles Medical Group Ltd
Raffles Medical Group Ltd provides integrated private healthcare services primarily in Singapore, Greater China, Vietnam, Cambodia, and Japan. The company operates through four segments: Healthcare Services, Hospital Services, Investment Holdings, and Insurance Services. Its Raffles Hospital, a tertiary care hospital that offers 24-hour acute and critical care, family medicine services, health sc… Read more
Raffles Medical Group Ltd (02M1) - Net Assets
Latest net assets as of June 2025: €1.03 Billion EUR
Based on the latest financial reports, Raffles Medical Group Ltd (02M1) has net assets worth €1.03 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.49 Billion) and total liabilities (€455.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.03 Billion |
| % of Total Assets | 69.45% |
| Annual Growth Rate | 2.93% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.63 |
Raffles Medical Group Ltd - Net Assets Trend (2021–2024)
This chart illustrates how Raffles Medical Group Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Raffles Medical Group Ltd (2021–2024)
The table below shows the annual net assets of Raffles Medical Group Ltd from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.06 Billion | +2.02% |
| 2023-12-31 | €1.04 Billion | +1.57% |
| 2022-12-31 | €1.03 Billion | +5.24% |
| 2021-12-31 | €976.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Raffles Medical Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 60996000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €609.96 Million | 58.10% |
| Other Components | €439.81 Million | 41.90% |
| Total Equity | €1.05 Billion | 100.00% |
Raffles Medical Group Ltd Competitors by Market Cap
The table below lists competitors of Raffles Medical Group Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Universal Health Realty Income Trust
NYSE:UHT
|
$548.70 Million |
|
STAAR Surgical Company
NASDAQ:STAA
|
$548.73 Million |
|
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
SHG:688221
|
$548.84 Million |
|
JOHNSON SVC. LS-10
F:5K7
|
$548.86 Million |
|
Xiamen Port Development Co Ltd
SHE:000905
|
$548.17 Million |
|
Odontoprev S.A
SA:ODPV3
|
$548.11 Million |
|
Three Squirrels
SHE:300783
|
$548.09 Million |
|
Beijing Tianyishangjia New Material Corp Ltd
SHG:688033
|
$547.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Raffles Medical Group Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,027,738,000 to 1,049,766,000, a change of 22,028,000 (2.1%).
- Net income of 62,243,000 contributed positively to equity growth.
- Dividend payments of 44,576,000 reduced retained earnings.
- New share issuances of 280,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €62.24 Million | +5.93% |
| Dividends Paid | €44.58 Million | -4.25% |
| Share Issuances | €280.00K | +0.03% |
| Other Changes | €4.08 Million | +0.39% |
| Total Change | €- | 2.14% |
Book Value vs Market Value Analysis
This analysis compares Raffles Medical Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.33x to 1.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.51 | €0.69 | x |
| 2022-12-31 | €0.55 | €0.69 | x |
| 2023-12-31 | €0.55 | €0.69 | x |
| 2024-12-31 | €0.56 | €0.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Raffles Medical Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.93%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.28%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.46x
- Recent ROE (5.93%) is below the historical average (9.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 8.76% | 11.63% | 0.47x | 1.61x | €-11.91 Million |
| 2022 | 14.15% | 17.40% | 0.54x | 1.51x | €41.97 Million |
| 2023 | 8.77% | 12.75% | 0.46x | 1.49x | €-12.62 Million |
| 2024 | 5.93% | 8.28% | 0.49x | 1.46x | €-42.73 Million |
Industry Comparison
This section compares Raffles Medical Group Ltd's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $1,597,936,276
- Average return on equity (ROE) among peers: 7.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Raffles Medical Group Ltd (02M1) | €1.03 Billion | 8.76% | 0.44x | $548.22 Million |
| China Resources Medical Holdings Company Limited (1PH) | $6.14 Billion | 6.37% | 0.28x | $264.86 Million |
| Apollo Medical Holdings Inc (3AM) | $510.64 Million | 13.50% | 0.70x | $820.67 Million |
| NUVERRA ENVIR SOL (3H5) | $548.43 Million | -8.67% | 2.25x | $95.85 Million |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.04 Billion | 6.61% | 0.54x | $9.60 Million |
| Medicover AB (5M0B) | $562.10 Million | 18.11% | 2.00x | $967.15 Million |
| Ambea AB (publ) (6MA) | $4.68 Billion | 7.82% | 2.82x | $937.47 Million |
| Eifelhöhen-Klinik AG (EIF) | $18.66 Million | 24.17% | 2.10x | $4.38 Million |
| Garofalo Health Care S.p.A (GHC) | $333.14 Million | 6.51% | 1.55x | $126.70 Million |
| GZ4 (GZ4) | $545.91 Million | -4.85% | 4.17x | $116.32 Million |